ReviewDrug safety2019
Pharmacovigilance Systems in Arab Countries: Overview of 22 Arab Countries.
Review in Drug safety, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 62 citations in OpenAlex.
- Current Pharmacovigilance Outsourcing Practices in Arab Countries.Drug safety · 2026Review
- ISoP MENA Chapter: Strategic Development and Future Directions Following a Decade of Strengthening Pharmacovigilance in the Middle East and North Africa.Drug safety · 2026Article
- Awareness of healthcare professional students towards pharmacovigilance and adverse drug reaction reporting at a Saudi Public University.BMC health services research · 2026Article
- The evolution of pharmacovigilance system in Bangladesh: present landscape and strategic priorities.Journal of pharmaceutical policy and practice · 2026Article
- Safety without the counter: transparency of online safety information for women's over-the-counter medicines across markets.Journal of pharmaceutical policy and practice · 2026Article
- Spontaneous adverse drug reaction reporting: potential facilitators perceived by community pharmacists in Egypt - a cross-sectional study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025Article
- Review
- Assessment of knowledge and perceptions of pharmacy students toward pharmacovigilance activities, and their predictors: a cross-sectional study in Palestine.BMC medical education · 2025Article
- 'Prevalence, experience and awareness of substandard and falsified medicines among the public and healthcare professionals in Jordan'.BMJ global health · 2025Article
- Characterizing Public Sentiments and Drug Interactions in the COVID-19 Pandemic Using Social Media: Natural Language Processing and Network Analysis.Journal of medical Internet research · 2025Article
- Building functional and sustainable pharmacovigilance systems: an analysis of pharmacovigilance development across high-, middle- and low-income countries.Therapeutic advances in drug safety · 2025Article
- Descriptive analysis of the national drug adverse events (AEs) database in Lebanon.Journal of pharmaceutical policy and practice · 2025Article
- Knowledge, counseling practices, and educational gaps related to drug-food interactions among healthcare professionals in Saudi Arabia: a cross-sectional study.Frontiers in medicine · 2025Article
- Global trends in pharmacovigilance-related events: a 30-year analysis from the 2019 global burden of disease study.International journal of clinical pharmacy · 2024Article
- Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Article
- Exploring the knowledge, perception, and practice of community pharmacists in Saudi Arabia toward pharmacovigilance and adverse drug reaction reporting. A nationwide survey.Scientific reports · 2024Article
- Exploring the community pharmacist's knowledge, attitude, and practices regarding adverse drug reactions and its reporting in the United Arab Emirates: a survey-based cross-sectional study.Therapeutic advances in drug safety · 2024Article
- Exploring pharmacovigilance practices and knowledge among healthcare professionals: A cross-sectional multicenter study.SAGE open medicine · 2024Article
- A narrative review of veterinary pharmacovigilance situations and prospects in East African countries.Frontiers in veterinary science · 2024Review
- The Role of ISoP in the Advancement of Pharmacovigilance in Low-and Middle-Income Countries (LMICs).Drug safety · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacovigilance has received much attention in Arab countries recently due to the development of new regulations. However, there are differences in the progression of pharmacovigilance systems by regulatory agencies in these countries because only some are able to meet the requirements for conducting pharmacovigilance activities. Only 45% of Arab countries are official members of the World Health Organization (WHO) Collaborating Centre for International Drug Monitoring. Countries such as Morocco, Tunisia, Saudi Arabia, Egypt, and Jordan are considered to be advanced pharmacovigilance countries, whereas other countries such as Libya, Yemen, and Palestine remain in the very early stages of implementing and developing pharmacovigilance systems. Countries such as Somalia, Djibouti, Mauritania, and Comoros Island have no pharmacovigilance system or culture. Asian Arab countries have some advantages over those in Africa because 50% of them are a part of the Gulf Cooperation Council (GCC), meaning that most of them can utilize similar approaches for the application of the majority of activities related to the healthcare system, including pharmacovigilance. Thus, participating in the GCC enables increased connections among these countries. However, one of the strengths in Africa is that Morocco is partnering with the WHO through the WHO Collaborating Center to enhance and strengthen pharmacovigilance across the Eastern Mediterranean Region and the Francophone and Arab countries. This partnership could have a role in enhancing the pharmacovigilance culture among African Arab countries. This review provides a general overview of the current situation regarding regulatory agencies related to pharmacovigilance in Arab countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.